Neurocardiac Predictors of Treatment Response to RTMS in Depression

NCT05139862 | Not Yet Recruiting

• 1 other identifier: H19-00648
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 1

Brief Summary

Heartbeat is controlled by the brain and is regular but flexible to change in response to environmental and internal stimuli. This feature is known as heart rate variability (HRV). Major depressive disorder (MDD) has been associated with diminished HRV and this is a reflection of abnormal brain function caused by MDD. Repetitive transcranial magnetic stimulation (rTMS) is a treatment that stimulates specific areas of the brain. The goal of this study is to test the hypothesis that rTMS induces changes in connectivity between the area of the brain stimulated with rTMS and deeper areas in the brain associated to heart rate regulation. 110 patients with TRD will be recruited and will undergo a concurrent TMS-fMRI session before receiving a course of iTBS to the L-DLPFC for 30 sessions at 120% rMT.

Conditions

Depression; Treatment Resistant Depression

Keywords

Repetitive Transcranial Magnetic Stimulation; rTMS; Neurostimulation; Heart Rate Variability; fMRI

Outcome Measures

Primary Outcomes (1)

• Change from Baseline in Depressive Symptoms using HDRS-17 Scale at Week 10

  The 17-item Hamilton Depression Rating Scale (HRSD-17) will be used as the primary outcome measure as well as the tool to establish severity cut off for eligibility (Hamilton, 1960). The scoring ranges from 0-52, with higher scores indicating more severe depression symptoms.

  Baseline and Week 10

Secondary Outcomes (2)

• Change from Baseline in Anxiety Symptoms using HAM-A Scale at Week 10

  Baseline and Week 10

• Change from Baseline in Depressive Symptoms using QIDS-16 Scale at Week 10

  Baseline and Week 10

Other Outcomes (1)

• Change from baseline in Heart Rate Variability at Week 10

  Baseline and Week 10

Study Arms (1)

Active iTBS

EXPERIMENTAL

Active intermittent theta-burst stimulation (iTBS) rTMS session on the left dorsolateral prefrontal cortex (L-DLPFC)

Device: Repetitive Transcranial Magnetic Stimulation

Interventions

Repetitive Transcranial Magnetic Stimulation DEVICE

This study utilizes intermittent theta burst stimulation (iTBS) to the left DLPFC.

Also known as: rTMS

Active iTBS

Eligibility Criteria

• Age: 19 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients will be included if they:
• are female or male;
• are outpatients;
• are voluntary and competent to consent to treatment;
• have a DSM 5 diagnosis of MDD, single or recurrent confirmed by Mini-International Neuropsychiatric Interview (MINI) version 6.0;
• are between the ages of 18 and 65 years;
• have failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of \> 3 in the current episode OR have been unable to tolerate at least two separate trials of antidepressants at less than the minimum adequate dose and/or duration (ATHF 1 or 2);
• A score ≥ 18 on the Hamilton Depression Rating Scale (HDRS-17 item);
• Have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening;
• Able to adhere to the treatment schedule;
• pass the TMS and MRI adult safety screening questionnaires.

You may not qualify if:

• Patients are excluded if they:
• have a history of substance use within the last 3 months;
• have a concomitant major unstable medical illness;
• have active suicidal intent;
• are pregnant;
• have a lifetime (MINI) diagnosis of any psychotic or bipolar disorder;
• have a MINI anxiety disorder or personality disorder assessed by a study investigator to be primary and causing greater impairment than MDD;
• have ever failed a course of ECT;
• have previously received rTMS;
• have any significant neurological disorder, any history of seizure (except those therapeutically induced by ECT), significant head trauma with loss of consciousness for \> 5 min;
• have any intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
• if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to study entry, with no anticipated change in the frequency of therapeutic sessions, or focus of therapeutic sessions over the duration of the study;
• have a clinically significant laboratory abnormality, in the opinion of the one of the principal investigators;
• are currently taking lorazepam greater than 2 mg daily (or equivalent) or any dose of an anticonvulsant, due to the potential to limit rTMS efficacy;
• have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview);

Sponsors & Collaborators

• University of British Columbia: lead
• Canadian Institutes of Health Research (CIHR): collaborator

Study Sites (1)

Non-Invasive Neurostimulation Therapies (NINET) Laboratory, UBC Department of Psychiatry

Vancouver, British Columbia, V6T 2A1, Canada

Location

MeSH Terms

Conditions

Depression; Depressive Disorder, Treatment-Resistant

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Behavioral Symptoms; Behavior; Depressive Disorder; Mood Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Magnetic Field Therapy; Therapeutics

Study Officials

• Fidel Vila-Rodriguez, M.D., Ph.D.

  Department of Psychiatry, UBC

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jessica Layton

CONTACT

604-822-7308; ninet.lab@ubc.ca

Fidel Vila-Rodriguez, M.D., Ph.D.

CONTACT

604-827-1361; ninet.lab@ubc.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator

Model Details: For MDD patients, the study will consist of six weeks of rTMS treatment using intermittent theta burst stimulation (iTBS) rTMS to the left DLPFC. Treatment will be administered daily, 5 days per week (i.e., 30 treatments).

Study Record Dates

• First Submitted: November 17, 2021
• First Posted: December 1, 2021
• Study Start: May 1, 2025
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: December 24, 2024

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)